# A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

> **NCT03387046** · PHASE2 · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 7 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DIETARY_SUPPLEMENT:** D-aspartate
- **DRUG:** Placebo
- **BIOLOGICAL:** IFN beta-1a
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT03387046
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-26
- **Primary completion:** 2019-01-11
- **Final completion:** 2019-01-11
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study was terminated early due to slow recruitment rate.
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03387046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03387046, "A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03387046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*